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Background: Cognitive impairment is one of the side effects of using anticholinergic medicines for overactive
bladder; however, its incidence has not been fully reported. We experienced two elderly Japanese patients with
overactive bladder who had temporary cognitive impairment caused by anticholinergic medicines.
Case presentation: The first case was a 79-year-old female patient to whom imidafenacin (0.2 mg) was administered
daily to control her frequent micturition and urgency. She was taking the following medicines: etizolam, triazolam,
captopril, bisoprolol, and amlodipine besylate. Her Hasegawa dementia rating scale-revised was impaired from 26/30
to 17/30 and recovered to 25/30 after the imidafenacin treatment was stopped. The second case was an 82-year-old
female patient to whom imidafenacin (0.2 mg) was administered daily for frequent micturition and urgency. She was
taking the following medicines: losartan potassium and clenbuterol. Her Hasegawa dementia rating scale-revised
decreased from 28/30 to 19/30 and recovered to 24/30 after the imidafenacin treatment was stopped. In our patients
who were taking multiple medicines, there is a possibility that medicines other than anticholinergics may have
caused cognitive impairment. We need to keep in mind that many elderly people take multiple medicines because
of comorbidity.
Conclusions: Anticholinergic medicines can cause cognitive impairment in elderly people, and attention should be
paid to cognition when elderly overactive bladder patients are treated with anticholinergic medicines.
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Cognitive impairment is one of the side effects of using
anticholinergic medicines for overactive bladder (OAB);
however, its incidence has not been fully reported. Oxy-
butynin has been shown to cause cognitive impairment
and delirium in elderly people [1]. However, no other re-
port of cognitive impairment caused by anticholinergic
medicines for OAB was found. Recently, newly devel-
oped anticholinergic medicines for OAB were found to
not affect cognition [2,3]. These newly developed anti-
cholinergic medicines for OAB are thought to be safe and
not cause cognitive impairment because their movement* Correspondence: torimoto@naramed-u.ac.jp
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unless otherwise stated.into the central nervous system is limited [4]. We experi-
enced two elderly Japanese patients with OAB who had
temporary cognitive impairment caused by anticholinergic
medicines.Case presentation
Case 1
A 79-year-old female patient presented to a neurologist
with a chief complaint of amnesia six months ago and
was found to have normal cognition, as a computed
tomography (CT) scan did not detect any organic brain
lesions and Hasegawa dementia rating scale-revised
(HDS-R) [5] was 26/30. She was taking the following
medicines: etizolam, triazolam, captopril, bisoprolol, and
amlodipine besylate.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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trol her frequent micturition and urgency. After one
month, the imidafenacin treatment was stopped because
her cognition was impaired (HDS-R, 17/30), although
the lower urinary tract symptoms (LUTS) improved. A
CT scan did not detect any brain lesions at that time.
After three weeks, her cognition recovered (HDS-R,
25/30). Then, tolterodine (4 mg) was administered daily
instead of imidafenacin; however, it was stopped because
of cognitive impairment (Figure 1).
Case 2
An 82-year-old female patient presented with a chief
complaint of mixed urinary incontinence that had
persisted for four months. She was taking losartan po-
tassium. Clenbuterol (40 μg) was administered daily
because stress urinary incontinence was predominant
over urge urinary incontinence. After one month, her
urinary incontinence improved. Three months later,
imidafenacin (0.2 mg) was administered daily for fre-
quent micturition and urgency. However, after two
weeks of treatment, her HDS-R decreased from 28/30
to 19/30, although the LUTS improved. At that time,
she was found to have normal cognition by a neur-
ologist because her mini mental scale examination
(MMSE) was 26/30 and a CT scan did not detect any
brain lesions. Imidafenacin administration was immedi-
ately stopped, and three weeks later, her HDS-R recov-
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Figure 1 Monitoring of cognitive function in Case 1. In Case 1, Hasega
administration and recovered after the stop of imidafenacin. Bar graph: Has
of voids.mirabegron (50 mg) was administered daily instead of
imidafenacin. Her cognition was stable as follows: her
HDS-R was 25/30 after one month, and her HDS-R and
MMSE were 26/30 and 23/30, respectively, after seven
months (Figure 2).
Discussion
Anticholinergics are the first choice for OAB and are
often administered to elderly people in whom the
prevalence of OAB is high [6]. While it has been re-
ported that anticholinergic medicines for OAB are safe
and do not cause cognitive impairment [4], anticholin-
ergics do in fact frequently induce reversible cognitive
impairment [7,8]. They were traditionally thought to
affect cognition and be high-risk medicines causing
cognitive impairment. There is good evidence that the
combination of multiple medicines can precipitate or
predispose to cognitive impairment. The American College
of Surgeons National Surgical Quality Improvement
Program (ACS NSQIP®)/American Geriatrics Society
(AGS) Best Practices Guidelines list strong anticholin-
ergic medicines for OAB, such as darifenacin, fesoter-
odine, flavoxate, oxybutynin, solifenacin, tolterodine,
and trospium, which may be avoided in elderly people
[9]. The adverse effects of anticholinergic medicines
on cognition depend on the strength or combination.
It has been reported that anticholinergic medicines
had a significantly high risk of causing cognitive im-
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Figure 2 Monitoring of cognitive function in Case 2. In Case 2, Hasegawa dementia rating scale-revised decreased after imidafenacin administration
and recovered after the stop of imidafenacin although mini mental scale examination was stable. Bar graph: Hasegawa dementia rating scale-revised, Line
graph: 24-hour number of voids, Filled triangle: mini mental scale examination.
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tients who were taking multiple medicines, there is a possi-
bility that medicines other than anticholinergics may have
caused cognitive impairment. We need to keep in mind
that many elderly people take multiple medicines because
of comorbidity.
Cystometry has become unnecessary to diagnose
patients as OAB since the Standardization Subcom-
mittee of the International Continence Society (ICS)
recognized OAB as a “symptom syndrome suggestive
of lower urinary tract dysfunction” which is specific-
ally defined as “urgency, with or without urge incon-
tinence, usually with frequency and nocturia” in 2002
[11]. Afterwards any medical doctors including pri-
mary care doctors can diagnose patients as OAB and
treat OAB mainly with anticholinergic medicines. We
may have to perform cystometry more aggressively to
detect detrusor overactivity in elderly patients who
have the risk of drug-induced cognitive impairment.
That may result in better selection of elderly patients
and allow doctors to avoid side effects of anticholin-
ergic medicines.
While MMSE is the global standard diagnostic method
for cognition, HDS-R is the standard method in Japan.
In our second case (Case 2), the diagnostic results were
different between MMSE and HDS-R. It is still debatable
which method is better for the diagnosis of cognitive
impairment [5].Conclusions
Anticholinergic medicines can cause cognitive impair-
ment in elderly people, and attention should be paid to
cognition when elderly OAB patients are treated with
anticholinergic medicines.Consent
Written informed consent was obtained from the pa-
tients for publication of these Case Reports and any
accompanying images. Copies of the written consent
are available for review by the Editor-in-Chief of this
journal.
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